ReviewFrom the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies
Section snippets
Association of the psoriatic disease state and CVD
In 1995, the association of psoriasis with diabetes mellitus (DM), obesity, heart failure, and hypertension (HTN) was first observed.10 Since then, cardiovascular risk factors have been demonstrated in numerous studies. In fact, some reports suggest psoriasis is an independent risk factor for cardiovascular morbidity.11, 12, 13 Patients with psoriasis may have a predisposition to DM and HTN,14 and several studies have shown higher rates of DM, HTN, hyperlipidemia, smoking, obesity, and
Association of therapeutic modalities and CVD
Given the increased risk of CVD, an area of interest has been evaluating how therapeutic modalities might modulate cardiovascular risk.
Biomarkers of inflammation
Treatment with TNF inhibitors (TNFi) has been shown to modify C-reactive protein, adiponectin, VEGF, and resistin. C-reactive protein is a predictor of CVD such as MI, peripheral arterial disease, and sudden cardiac death.90, 91, 92 Adiponectin has anti-inflammatory, antiatherogenic, and antidiabetic properties,93, 94 VEGF may reflect inflammation and hypoxia such as in acute MI,95 and resistin is related to insulin resistance.96 Etanercept was shown to decrease levels of C-reactive protein in
Conclusion
Currently, there is not enough evidence to recommend therapies for psoriasis solely based on cardiovascular impact. However, if systemic therapy is a consideration in the setting of CVD or risk, it would appear that, based on current data, TNFi and MTX offer the best evidence of benefit. As the initial clinician seen for most cases of psoriasis, the dermatologist should actively screen patients with severe disease for cardiovascular risk factors and provide appropriate counseling, treatment,
References (150)
- et al.
Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions
J Invest Dermatol
(2010) - et al.
Disease concomitance in psoriasis
J Am Acad Dermatol
(1995) - et al.
The risk of stroke in patients with psoriasis
J Invest Dermatol
(2009) - et al.
Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom
J Invest Dermatol
(2012) - et al.
Prevalence of cardiovascular risk factors in patients with psoriasis
J Am Acad Dermatol
(2006) - et al.
Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations: results of a large population-based Dutch cohort
J Invest Dermatol
(2010) - et al.
Psoriasis and cardiovascular risk: strength in numbers
J Invest Dermatol
(2010) - et al.
Very severe psoriasis is associated with increased noncardiovascular mortality but not with increased cardiovascular risk
J Invest Dermatol
(2011) - et al.
The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study
J Am Acad Dermatol
(2007) - et al.
Impaired coronary flow reserve in young patients affected by severe psoriasis
Atherosclerosis
(2012)
Coronary artery disease in patients with psoriasis referred for coronary angiography
Am J Cardiol
The cytokine and chemokine network in psoriasis
Clin Dermatol
Vascular endothelial growth factor (VEGF) in the pathogenesis of psoriasis–a possible target for novel therapies?
J Dermatol Sci
Immunopathogenesis and role of T cells in psoriasis
Clin Dermatol
The cardiovascular stress of photochemotherapy (PUVA)
J Am Acad Dermatol
A randomized comparison of narrow-band TL-01 phototherapy and PUVA photochemotherapy for psoriasis
J Am Acad Dermatol
Narrowband UVB phototherapy in skin conditions beyond psoriasis
J Am Acad Dermatol
Long-term safety of retinoid therapy
J Am Acad Dermatol
Acitretin in psoriasis: an overview of adverse effects
J Am Acad Dermatol
The safety of etretinate as long-term therapy for psoriasis: results of the etretinate follow-up study
J Am Acad Dermatol
Elevation of fasting serum lipids in patients treated with low-dose cyclosporine for severe plaque-type psoriasis: an assessment of clinical significance when viewed as a risk factor for cardiovascular disease
J Am Acad Dermatol
Mycophenolate mofetil attenuates plaque inflammation in patients with symptomatic carotid artery stenosis
Atherosclerosis
Cardiovascular morbidity and mortality in rheumatoid arthritis
Am J Med
Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study
Lancet
Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease
Am J Cardiol
High-sensitivity C-reactive protein: clinical importance
Curr Probl Cardiol
Adiponectin as an anti-inflammatory factor
Clin Chim Acta
Pathogenesis and therapy of psoriasis
Nature
Immunopathogenesis of psoriasis
Clin Rev Allergy Immunol
Cardiovascular comorbidities in psoriasis and psoriatic arthritis: pathogenesis, consequences for patient management, and future research agenda; a report from the GRAPPA 2009 annual meeting
J Rheumatol
A proposed classification of the immunological diseases
PLoS Med
Cytokine milieu in psoriasis and cardiovascular disease may explain the epidemiological findings relating these 2 diseases
Arch Dermatol
Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality
Arch Dermatol
Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis
J Am Acad Dermatol
The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity
Exp Dermatol
Risk of myocardial infarction in patients with psoriasis
JAMA
The risk of mortality in patients with psoriasis: results from a population-based study
Arch Dermatol
Psoriasis patients show signs of insulin resistance
Br J Dermatol
Changes in the sex hormone profile of male patients with moderate-to-severe plaque-type psoriasis under systemic therapy: results of a prospective longitudinal pilot study
Arch Dermatol Res
Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study
J Eur Acad Dermatol Venereol
Cardiovascular disease and classic cardiovascular risk factors in patients with psoriasis
Int J Dermatol
Comedication related to comorbidities: a study in 1203 hospitalized patients with severe psoriasis
Br J Dermatol
Psoriasis and risk of incident myocardial infarction, stroke or transient ischemic attack: an inception cohort study with a nested case-control analysis
Br J Dermatol
Psoriasis and risk of atrial fibrillation and ischemic stroke: a Danish nationwide cohort study
Eur Heart J
Psoriasis carries an increased risk of venous thromboembolism: a Danish nationwide cohort study
PLoS One
Psoriasis: a possible risk factor for development of coronary artery calcification
Br J Dermatol
Pathogenic mechanisms shared between psoriasis and cardiovascular disease
Int J Med Sci
Prognosis following first-time myocardial infarction in patients with psoriasis: a Danish nationwide cohort study
J Intern Med
Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the general practice research database
Eur Heart J
Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study
J Intern Med
Cited by (124)
Using Guidelines of Care to Lower Cardiovascular Risk in Patients with Psoriasis
2024, Dermatologic Clinics2022 Taiwanese Dermatological Association (TDA), Taiwanese Association for Psoriasis and Skin Immunology (TAPSI), and Taiwan Society of cardiology (TSOC) joint consensus recommendations for the management of psoriatic disease with attention to cardiovascular comorbidities
2023, Journal of the Formosan Medical AssociationThe risk of organ-based comorbidities in psoriasis: a systematic review and meta-analysis
2022, Anais Brasileiros de DermatologiaCitation Excerpt :These conclusions need more data for further confirmation. The pathogenesis of psoriasis and organ-based comorbidities may be mediated by certain representative cytokines, e.g., Interleukin-17 (IL-17),50–53 Interleukin-23 (IL-23),54 and Tumour Necrosis Factor-ɑ (TNF-ɑ).55,56 They can reach the body anywhere through the blood circulation and may mediate systemic inflammatory responses in psoriasis.57–61
Perspectives of phytotherapeutics: Diagnosis and cure
2021, Phytomedicine: A Treasure of Pharmacologically Active Products from PlantsKardiovaskuläre Komorbidität bei Psoriasis – Entzündung in Psoriasis betrifft nicht nur die Haut
2023, JDDG - Journal of the German Society of Dermatology
Funding sources: None.
Disclosure: Dr Van Voorhees has served on advisory boards for Amgen, Abbott Laboratories, Genentech, Novartis, Warner Chilcott, Centocor/Janssen Biotech, and LEO Pharma; has been an investigator and consultant for Amgen; and has been a speaker for Amgen, Abbott Laboratories, and Centocor/Janssen Biotech. Dr Bagel has served as consultant, on advisory boards, and as a speaker and investigator for Amgen and Abbott Laboratories. Dr Lebwohl has served as consultant and investigator for Abbott Laboratories, Amgen, Celgene, Eli Lilly & Co, Janssen Biotech, and LEO Pharma; as an investigator for Ranbaxy; and as a consultant for Anacor Pharmaceuticals, BioLineRX, Dermipsor, Galderma, GlaxoSmithKline-Stiefel, Maruho, Novartis, Pfizer, and Valeant. Dr Blauvelt has served on advisory boards and as investigator and consultant for Janssen Biotech, Novartis, and Eli Lilly & Co; as a speaker for Janssen Biotech; and as an investigator for Abbott Laboratories, Amgen, and Celgene. Dr Hsu has served on advisory boards for Abbott Laboratories, Amgen, Biogen Idec, Centocor/Janssen Biotech, and Genentech; and has been an investigator for Centocor/Janssen Biotech. Dr Weinberg has served as a speaker for Abbott Laboratories, Amgen, and Genentech, and has performed clinical research for Amgen, Celgene, and Janssen Biotech. Drs Hugh and Nijhawan have no conflicts of interest to declare.